<DOC>
	<DOCNO>NCT02835118</DOCNO>
	<brief_summary>This study aim assess safety , tolerability , pharmacokinetics ( PK ) oral dos surotomycin ( CB-183,315 ) administer 14 consecutive day healthy male female .</brief_summary>
	<brief_title>A Study Ascending Multiple Doses Oral Surotomycin Healthy Participants ( MK-4261-009 )</brief_title>
	<detailed_description />
	<mesh_term>Diarrhea</mesh_term>
	<criteria>Has evidence prior chronic gastrointestinal inflammatory disease inflammatory bowel disease Electrocardiogram ( ECG ) show clinically significant abnormality Is good health Pregnant lactating female Has prior exposure surotomycin Has receive investigational drug participate experimental procedure within1 month prior study entry least 6 half life last intake study drug Participants 18 49 year age take regular , prescribe , overthecounter medication Has significant concurrent therapy Has positive drug screen Has positive human immunodeficiency virus ( HIV ) , Hepatitis B , Hepatitis C screen Has donate blood blood product 60 day precede screening Is active intravenous drug user abuse alcohol Has malignancy within last 5 year Has inadequate protection pregnancy conduct study 1 month last dose study drug Has receive antibiotic within 30 day prior first dose study drug Has know hypersensitivity daptomycin</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>